Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.
Tesla stock rises sharply extending gains for a second day, Nvidia and Palantir shares trade higher as tech stocks bounce ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback